RBC Capital Downgrades Pliant Therapeutics (PLRX) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JPMorgan Downgrades Pliant Therapeutics (PLRX) to Neutral
February 10, 2025 8:58 AM ESTJPMorgan analyst Eric Joseph downgraded Pliant Therapeutics (NASDAQ: PLRX) from Overweight to Neutral.
The analyst comments "We are downgrading PLRX shares from Overweight to Neutral on the back of the voluntary pause of the BEACON-IPF (bexotegrast in IPF) trial announced Friday... More
H.C. Wainwright Downgrades Pliant Therapeutics (PLRX) to Neutral
February 10, 2025 6:04 AM ESTH.C. Wainwright analyst Ed Arce downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral.
The analyst comments "Our Take. This could turn out to be nothing, or it could spell the end for bexotegrast, if its a serious toxicity event(s) deemed likely due to study drug. Immediately following Friday's press... More
Oppenheimer Downgrades Pliant Therapeutics (PLRX) to Perform
February 10, 2025 6:03 AM ESTOppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (NASDAQ: PLRX) from Outperform to Perform.
The analyst comments "Friday afternoon PLRX announced a voluntary pause to the enrollment, and dosing, of their Phase 2b BEACON trial based on the recommendation of their DSMB (press... More
